Neoadjuvant removal of DCIS helps identify HER2+ nonsurgical trial candidates
In evaluating the safety of eliminating surgery for patients who are exceptional responders to neoadjuvant systemic therapy, eradication of both...
Bioimpedance spectroscopy may better identify lymphedema progression
In an interim analysis from the PREVENT trial, there was a 10% absolute reduction and 67% relative reduction in lymphedema progression in the...
Subcutaneous or IV trastuzumab? Take your pick
Long-term follow-up of women with early, HER2-positive breast cancer showed similar efficacy and safety for subcutaneous or intravenous...
Novel CAR T, anti-PD-1 combo shows promise in MPD
ATLANTA – Intrapleurally administered, mesothelin-targeted CAR T-cell therapy combined with PD-1 inhibition showed antitumor activity without...
FDA proposes updates to mammography regulations
Key among the proposed changes is the addition of breast density information to notices for both patients and doctors.
FDA approves another trastuzumab biosimilar for HER2-positive breast cancer, gastric cancer
The Food and Drug Administration has approved Trazimera (trastuzumab-qyyp), a biosimilar of ...
FDA approves Tecentriq plus Abraxane in breast cancer
The immunotherapy regimen received accelerated approval for the treatment of PD-L1-positive triple-negative breast cancer in adults.
FDA urges caution with robotic devices in cancer surgery
The FDA cites evidence that the use of robotically assisted surgical devices for treatment or prevention of cancers may be associated with...
Breast Cancer Tumor Board
Why Am I Being Treated Like a Female Breast Cancer Patient?
A joint patient and oncologist perspective on treating male breast cancer in the VA.